AstraZeneca signs potential $240M R&D deal with Alchemia

04/24/2013 | Genetic Engineering & Biotechnology News

Alchemia and AstraZeneca agreed to collaborate in the discovery and potential development of novel small molecules against multiple targets using the former's Diversity Scanning Array and Versatile Assembly on Stable Templates chemistry technology. AstraZeneca will pay Alchemia an undisclosed upfront fee, research funding, and as much as $240 million in milestone fees plus royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA